Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Equity Income (2019 - 2020)

Avalo Therapeutics' Equity Income history spans 2 years, with the latest figure at -$1.9 million for Q2 2020.

  • For Q2 2020, Equity Income changed N/A year-over-year to -$1.9 million; the TTM value through Mar 2021 reached -$1.9 million, down 126.24%, while the annual FY2020 figure was $5.2 million, 9556.6% up from the prior year.
  • Equity Income reached -$1.9 million in Q2 2020 per AVTX's latest filing, down from $7.1 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $7.1 million in Q1 2020 to a low of -$1.9 million in Q2 2020.